API | inotersen

inotersen (tegsedi) Report issue

Biologics Nucleic acid Orphan Drug ^FDA Approved ^FDA Fast Track ^FDA Priority Review ^FDA

AACT Drugs@FDA PubChem

Active Ingredient History

NOW

Inotersen, sold under the brand name Tegsedi, is a 2'-O-(2-methoxyethyl) (2'-MOE) antisense oligonucleotide medication used for the treatment of nerve damage in adults with hereditary transthyretin-mediated amyloidosis. The sequence is TCTTG GTTACATGAA ATCCC, where C is methylated C, and the first and third section are MOE-modified. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Transthyretin (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Drug Pricing (per unit)

United States

$6452.9750 - $8650.0000

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

gsk 299872 | inotersen sodium | isis 420915

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (1)

Amyloidosis (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Amyloidosis (Phase 2)

Polyradiculoneuropathy (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue